{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T18:15:01Z","timestamp":1720116901014},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.intimp.2023.109804","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T12:43:51Z","timestamp":1675860231000},"page":"109804","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Patient-tailored dose reduction of tumor necrosis factor inhibitors in axial spondyloarthritis"],"prefix":"10.1016","volume":"116","author":[{"given":"Jin-Xian","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Heng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0005","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2023.109804_b0010","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"Update of the american college of rheumatology\/spondyloarthritis association of america\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondyloarthritis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0015","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2023.109804_b0020","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","author":"Ramiro","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2023.109804_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine."},{"issue":"7","key":"10.1016\/j.intimp.2023.109804_b0030","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/rheumatology\/keu461","volume":"54","author":"Gonz\u00e1lez-\u00c1lvaro","year":"2015","journal-title":"Rheumatology (Oxford)."},{"issue":"3","key":"10.1016\/j.intimp.2023.109804_b0035","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/1756-185X.13510","article-title":"2018 APLAR axial spondyloarthritis treatment recommendations","volume":"22","author":"Tam","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2023.109804_b0040","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","article-title":"Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review","volume":"55","author":"Navarro-Comp\u00e1n","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.intimp.2023.109804_b0045","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","article-title":"Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective","volume":"56","author":"Edwards","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.intimp.2023.109804_b0050","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1093\/rheumatology\/keab902","article-title":"Risk of flare after tapering or withdrawal of biologic\/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis","volume":"61","author":"Uhrenholt","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0055","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/acr.24184","article-title":"Tumor necrosis factor inhibitor dose reduction for axial spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Lawson","year":"2021","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"112","key":"10.1016\/j.intimp.2023.109804_b0060","article-title":"Tapering biologics in axial spondyloarthritis: a systematic literature review","volume":"20","author":"Saoussen","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109804_b0065","doi-asserted-by":"crossref","first-page":"e028517","DOI":"10.1136\/bmjopen-2018-028517","volume":"9","author":"Uhrenholt","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.intimp.2023.109804_b0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10067-007-0674-2","article-title":"Etanercept 25 mg\/week is effective enough to maintain remission for ankylosing spondyloarthritis among Korean patients","volume":"27","author":"Lee","year":"2008","journal-title":"Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2023.109804_b0075","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","article-title":"Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondyloarthritis: a retrospective analysis","volume":"29","author":"Lee","year":"2010","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109804_b0080","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","article-title":"Low doses of etanercept can be effective in ankylosing spondyloarthritis patients who achieve remission of the disease","volume":"30","author":"Navarro-Comp\u00e1n","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2023.109804_b0085","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondyloarthritis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics."},{"key":"10.1016\/j.intimp.2023.109804_b0090","first-page":"289845","article-title":"Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondyloarthritis: a two-year pilot study","author":"M\u00f6rck","year":"2013","journal-title":"Mediators Inflamm."},{"issue":"5","key":"10.1016\/j.intimp.2023.109804_b0095","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-013-2372-6","article-title":"Low doses of etanercept can be effective to maintain remission in ankylosing spondyloarthritis patients","volume":"33","author":"De Stefano","year":"2014","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109804_b0100","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3899\/jrheum.141335","article-title":"Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondyloarthritis? A randomized control trial","volume":"42","author":"Yates","year":"2015","journal-title":"J Rheumatol."},{"key":"10.1016\/j.intimp.2023.109804_b0105","first-page":"174","article-title":"Patient-tailored dose reduction of TNF-\u03b1 blocking agents in ankylosing spondyloarthritis patients with stable low disease activity in daily clinical practice","volume":"33(2)","author":"Arends","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2023.109804_b0110","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3899\/jrheum.141128","article-title":"Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity","volume":"42","author":"Plasencia","year":"2015","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2023.109804_b0115","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/rheumatology\/kew269","article-title":"The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondyloarthritis and psoriatic arthritis","volume":"55","author":"Fong","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","article-title":"A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondyloarthritis over 1 year: a propensity score-matched cohort study","volume":"75","author":"Z\u00e1vada","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2023.109804_b0125","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3899\/jrheum.170057","article-title":"Maintenance of low disease activity following tumor necrosis factor inhibitor dose tapering in ankylosing spondyloarthritis","volume":"44","author":"Steel","year":"2017","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0130","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s10067-018-4084-4","article-title":"Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission","volume":"37","author":"Chen","year":"2018","journal-title":"Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109804_b0135","first-page":"884","article-title":"Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis","volume":"36","author":"Lian","year":"2018","journal-title":"Clin Exp Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109804_b0140","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/art.40542","article-title":"Golimumab tapering strategy based on serum drug levels in patients with spondyloarthritis","volume":"70","author":"Redondo","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109804_b0145","doi-asserted-by":"crossref","first-page":"700","DOI":"10.5114\/aoms.2018.76141","article-title":"Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China","volume":"15","author":"Li","year":"2019","journal-title":"Arch Med Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"REDES-TNF investigators. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratac\u00f3s","year":"2019","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13075-019-1943-6","article-title":"Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2023.109804_b0160","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"10.1016\/j.intimp.2023.109804_b0165","first-page":"633","article-title":"Relapse of ankylosing spondylitis and its predictors after withdrawal of tumor necrosis factor-\u03b1 inhibitors: a 52-week follow-up study","volume":"41","author":"Tang","year":"2021","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao."},{"issue":"8","key":"10.1016\/j.intimp.2023.109804_b0170","article-title":"Structural lesion progression of the sacroiliac joint and clinical features in axspa during TNFi reduction: a retrospective cohort study","volume":"7","author":"Mo","year":"2021","journal-title":"Front. Med. (Lausanne)."},{"issue":"3","key":"10.1016\/j.intimp.2023.109804_b0175","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s12325-021-01995-1","article-title":"Disease activity-guided stepwise tapering but not discontinuation of biologics is a feasible therapeutic strategy for patients with ankylosing spondyloarthritis: real-world evidence","volume":"39","author":"Ye","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.intimp.2023.109804_b0180","doi-asserted-by":"crossref","unstructured":"H. Harman, N. Kaban, Is tapering or discontinuation of biologic treatment in patients with radiographic and nonradiographic axial spondyloarthritis reasonable? : Alocal cohort study. Z Rheumatol. English, 2022. doi:10.1007\/s00393-022-01226-0. Epub ahead of print. PMID: 35672504.","DOI":"10.1007\/s00393-022-01226-0"},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"4 Suppl 78","key":"10.1016\/j.intimp.2023.109804_b0190","first-page":"S37","article-title":"Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease","volume":"31","author":"Song","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"4 Suppl 78","key":"10.1016\/j.intimp.2023.109804_b0195","first-page":"S43","article-title":"Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease","volume":"31","author":"Baraliakos","year":"2013","journal-title":"Clin Exp Rheumatol."},{"issue":"11","key":"10.1016\/j.intimp.2023.109804_b0200","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1093\/rheumatology\/keaa268","article-title":"Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis","volume":"59","author":"Cruz-Machado","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0205","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/annrheumdis-2015-208593","article-title":"Preliminary definitions of \u2018flare\u2019 in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2023.109804_b0210","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Assessment of SpondyloArthritis international Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0215","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2017-212178","article-title":"ASAS-FLARE study group. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS","volume":"77","author":"Molto","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"10.1016\/j.intimp.2023.109804_b0220","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/1756-185X.14423","article-title":"The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: A nation-wide, population-based real-world study","volume":"25","author":"Huang","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2023.109804_b0225","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00296-016-3428-0","article-title":"Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy","volume":"36","author":"Almirall","year":"2016","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0230","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1756-185X.14473","article-title":"Current aspects for the treatment of axial spondyloarthritis","volume":"26","author":"Ku","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0235","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/rheumatology\/keab741","article-title":"Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study","volume":"61","author":"Michielsens","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2023.109804_b0240","article-title":"Low dose of infliximab is inadequate in most patients with spondylarthropathies","author":"Sidiropoulos","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109804_b0245","first-page":"959","article-title":"Infliximab in ankylosing spondyloarthritis: a prospective observational inception cohort analysis of efficacy and safety","volume":"29","author":"Maksymowych","year":"2002","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2023.109804_b0250","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/kel156","article-title":"Low-dose infliximab treatment for ankylosing spondyloarthritis\u2013clinically- and cost-effective","volume":"45","author":"Jois","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.intimp.2023.109804_b0255","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10067-021-06018-6","article-title":"Presence of subclinical inflammation in axial spondyloarthritis patients with NSAID\/anti-TNF-\u03b1 drug-induced clinical remission","volume":"41","author":"Zong","year":"2022","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.109804_b0260","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/rheumatology\/keab565","article-title":"Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.intimp.2023.109804_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105358","article-title":"Factors associated with drug-free remission at 5-year in early onset axial spondyloarthritis patients: data from the DESIR cohort","volume":"89","author":"Ruyssen-Witrand","year":"2022","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.intimp.2023.109804_b0270","doi-asserted-by":"crossref","unstructured":"Nissen M, Delcoigne B, Di Giuseppe D, Jacobsson L, Hetland ML, Ciurea A, Nekvindova L, Iannone F, Akkoc N, Sokka-Isler T, Fagerli KM, Santos MJ, Codreanu C, Pombo-Suarez M, Rotar Z, Gudbjornsson B, van der Horst-Bruinsma I, Loft AG, M\u00f6ller B, Mann H, Conti F, Yildirim Cetin G, Relas H, Michelsen B, Ribeiro PA, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson \u00c1J, Askling J, Glintborg B, Lindstr\u00f6m U. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis. Rheumatology (Oxford). 2022:keac174. 10.1093\/rheumatology\/keac174. Epub ahead of print. PMID: 35323903.","DOI":"10.1093\/rheumatology\/keac174"},{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0275","first-page":"2398","article-title":"Tapering of TNF inhibitors in axial spondyloarthritis in routine care - 2-year clinical and MRI outcomes and predictors of successful tapering","volume":"61","author":"Wetterslev","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2023.109804_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152078","article-title":"Predictors of remission in people with axial spondyloarthritis: A systematic literature review","volume":"56","author":"Pinto","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.intimp.2023.109804_b0285","doi-asserted-by":"crossref","first-page":"e14620","DOI":"10.1097\/MD.0000000000014620","article-title":"A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondyloarthritis patients","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40744-021-00279-y","article-title":"Predictive value of active sacroiliitis in mri for flare among chinese patients with axial spondyloarthritis in remission","volume":"8","author":"Zheng","year":"2021","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.intimp.2023.109804_b0295","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/ou570o","article-title":"Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors","author":"Hern\u00e1ndez-Breijo","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109804_b0300","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.12998\/wjcc.v8.i7.1213","article-title":"Clinical significance and prognostic value of tumor necrosis factor-\u03b1 and dickkopf related protein-1 in ankylosing spondylitis","volume":"8","author":"Xiong","year":"2020","journal-title":"World J. Clin. Cases."},{"issue":"8","key":"10.1016\/j.intimp.2023.109804_b0305","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/1756-185X.14353","article-title":"Measurement of pre-treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients","volume":"25","author":"Peng","year":"2022","journal-title":"Int J Rheum Dis."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0310","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12891-019-2647-4","article-title":"LINC00311 is overexpressed in ankylosing spondylitis and predict treatment outcomes and recurrence","volume":"20","author":"Zhong","year":"2019","journal-title":"BMC Musculoskelet. Disord."},{"issue":"10","key":"10.1016\/j.intimp.2023.109804_b0315","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/acr.23768","article-title":"Detection of flares by decrease in physical activity, collected using wearable activity trackers in rheumatoid arthritis or axial spondyloarthritis: an application of machine learning analyses in rheumatology","volume":"71","author":"Gossec","year":"2019","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"10.1016\/j.intimp.2023.109804_b0320","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","article-title":"Key findings towards optimising adalimumab treatment: the concentration-effect curve","volume":"74","author":"Pouw","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2023.109804_b0325","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/kex474","article-title":"Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study","volume":"57","author":"Balsa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2023.109804_b0330","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1873-3","article-title":"REMINEA study Group. Withdrawal of infliximab therapy in ankylosing spondyloarthritis in persistent clinical remission, results from the REMINEA study","author":"Moreno","year":"2019","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0335","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.23167","article-title":"French Ankylosing spondyloarthritis Infliximab Network. Maintenance of infliximab treatment in ankylosing spondyloarthritis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment","volume":"58","author":"Breban","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.intimp.2023.109804_b0340","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","article-title":"Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions","volume":"75","author":"Schett","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2023.109804_b0345","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.rdc.2020.01.013","article-title":"Axial spondyloarthritis in the era of precision medicine","volume":"46","author":"van Bentum","year":"2020","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"4","key":"10.1016\/j.intimp.2023.109804_b0350","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/BOR.0b013e3283620e04","article-title":"Hip disease in ankylosing spondylitis","volume":"25","author":"Vander Cruyssen","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.intimp.2023.109804_b0355","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/471319","article-title":"Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept","volume":"2014","author":"Raffeiner","year":"2014","journal-title":"Case Rep. Med."},{"issue":"13","key":"10.1016\/j.intimp.2023.109804_b0360","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/tvst.10.13.29","article-title":"A novel clinical five-risk factor panel for individualized recurrence risk assessment of patients with acute anterior uveitis","volume":"10","author":"Ji","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.intimp.2023.109804_b0365","doi-asserted-by":"crossref","unstructured":"S.T. Angeles-Han, S. Ringold, T. Beukelman, D. Lovell, C.A. Cuello, M.L. Becker, R.A. Colbert, B.M. Feldman, G.N. Holland, P.J. Ferguson, H. Gewanter, J. Guzman, J. Horonjeff, P.A. Nigrovic, M.J. Ombrello, M.H. Passo, M.L. Stoll, C.E. Rabinovich, H.N. Sen, R. Schneider, O. Halyabar, K. Hays, A.A. Shah, N. Sullivan, A.M. Szymanski, M. Turgunbaev, A. Turner, J. Reston, American College of Rheumatology\/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 2019 Jun;71(6):864-877. 10.1002\/art.40885. Epub 2019 Apr 25. PMID: 31021511; PMCID: PMC6788287.","DOI":"10.1002\/art.40885"},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0370","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semarthrit.2018.11.004","article-title":"Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis","volume":"49","author":"Heiligenhaus","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.intimp.2023.109804_b0375","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Fundamentals of Care for uveitis international consensus group. guidance on noncorticosteroid systematicimmunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (focus) initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.intimp.2023.109804_b0380","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/09273948.2020.1850799","article-title":"Drug-induced sarcoid uveitis with biologics","volume":"30","author":"Sobolewska","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0385","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and colitis organisation topical review on treatment withdrawal [\u2018Exit Strategies\u2019] in Inflammatory Bowel Disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J. Crohns Colitis"},{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0390","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol."},{"issue":"9","key":"10.1016\/j.intimp.2023.109804_b0395","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/1756-185X.14388","article-title":"Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis","volume":"25","author":"Campos","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0400","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109804_b0405","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2023.109804_b0410","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1093\/rheumatology\/keac295","article-title":"The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs","volume":"61","author":"Tucker","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0415","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/1756-185X.14474","article-title":"Current treatment strategies and recommendations in psoriatic arthritis","volume":"26","author":"Kao","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0420","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jaad.2018.12.018","article-title":"TNF-\u03b1 inhibitor-induced psoriasis: a decade of experience at the Cleveland Clinic","volume":"83","author":"Mazloom","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"112","key":"10.1016\/j.intimp.2023.109804_b0425","doi-asserted-by":"crossref","first-page":"109207","DOI":"10.1016\/j.intimp.2022.109207","article-title":"Benefits of tumor necrosis factor inhibitors for cardiovascular disease in ankylosing spondylitis","volume":"5","author":"Huang","year":"2022","journal-title":"Int Immunopharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109804_b0430","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1093\/rheumatology\/keab082","article-title":"Club Rhumatismes et Inflammations (CRI). TNF inhibitors for the management of inflammatory heart disease in spondyloarthritis: french multicentre case-series and literature review","volume":"60","author":"Tennenbaum","year":"2021","journal-title":"Rheumatol. (Oxford)"},{"issue":"12","key":"10.1016\/j.intimp.2023.109804_b0435","doi-asserted-by":"crossref","first-page":"e0168958","DOI":"10.1371\/journal.pone.0168958","article-title":"Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondyloarthritis","volume":"11","author":"Park","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.intimp.2023.109804_b0440","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","article-title":"Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial","volume":"77","author":"van der Heijde","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2023.109804_b0445","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/acr.23097","article-title":"Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors","volume":"69","author":"Maas","year":"2017","journal-title":"Arthrit. Care Res (Hoboken)."},{"issue":"3","key":"10.1016\/j.intimp.2023.109804_b0450","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3904\/kjim.2015.30.3.391","article-title":"Predictive factors of radiographic progression in ankylosing spondylitis","volume":"30","author":"Kim","year":"2015","journal-title":"Korean J. Int. Med."},{"issue":"11","key":"10.1016\/j.intimp.2023.109804_b0455","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.3899\/jrheum.161401","article-title":"Radiographic evidence of hip joint recovery in patients with ankylosing spondylitis after treatment with anti-tumor necrosis factor agents: a case series","volume":"44","author":"Song","year":"2017","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109804_b0460","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s10067-020-05519-0","article-title":"Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature","volume":"40","author":"Rocha","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109804_b0465","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s10067-013-2263-x","article-title":"Absence of radiographic progression of hip arthritis during infliximab treatment for ankylosing spondylitis","volume":"32","author":"Konsta","year":"2013","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109804_b0470","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0394632016656013","article-title":"Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population","volume":"29","author":"Li","year":"2016","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0475","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s10067-019-04466-9","article-title":"Clinical and MRI response to dose reduction of an etanercept-biosimilar for hip arthritis in patients with ankylosing spondylitis: an observational, retrospective cohort study","volume":"38","author":"Huang","year":"2019","journal-title":"Clin. Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2023.109804_b0480","article-title":"The clinical and MRI effect of TNF-\u03b1 inhibitors in spondyloarthritis patients with hip involvement: a real-world observational clinical study","volume":"29","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0485","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/1573397117666211012110212","article-title":"Associated factors with the severity of hip involvement in spondyloarthritis and efficacy of TNF \u03b1 inhibitors in these patients","volume":"18","author":"Slouma","year":"2022","journal-title":"Curr. Rheumatol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0490","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13075-020-02188-x","article-title":"Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis","volume":"22","author":"Vinson","year":"2020","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0495","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10067-020-05209-x","article-title":"Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action","volume":"40","author":"Rodrigues-Manica","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109804_b0500","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-017-3965-2","article-title":"Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment","volume":"37","author":"Chen","year":"2018","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109804_b0505","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12891-020-03247-9","article-title":"Amongst patients taking biologic therapies for axial spondyloarthritis, which factors are associated with work non-participation?","volume":"21","author":"Nadin","year":"2020","journal-title":"BMC Musculoskelet. Disord."},{"issue":"6","key":"10.1016\/j.intimp.2023.109804_b0510","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11926-021-01003-z","article-title":"Value-based healthcare in rheumatology: axial spondyloarthritis and beyond","volume":"23","author":"Liew","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"issue":"Suppl 78","key":"10.1016\/j.intimp.2023.109804_b0515","first-page":"S47","article-title":"Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?","volume":"4","author":"Kiltz","year":"2013","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923001273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923001273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T12:23:38Z","timestamp":1719231818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923001273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":103,"alternative-id":["S1567576923001273"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109804","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-tailored dose reduction of tumor necrosis factor inhibitors in axial spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109804"}}